Ovarian cancer is a highly metastatic disease. Lysophosphatidic acid (LPA) levels are elevated in ascites from ovarian cancer patients, but its potential role in ovarian cancer metastasis has just begun to be revealed. In this work, we show that LPA stimulates invasion of primary ovarian cancer cells, but not ovarian epithelial or borderline ovarian tumor cells, although these benign cells indeed respond to LPA in cell migration. We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs). TIMP2 and TIMP3 play functional role in LPA-induced invasion as negative regulators. G i protein, phosphatidylinositol-3 kinase (PI3K), p38 mitogenactivated protein kinase (MAPK), cytosolic phospholipase A 2 and urokinase type plasminogen activator (uPA) are required for LPA-induced cells invasion. TIMP3 may affect two independent downstream targets, vascular endothelial growth factor receptor and p38 MAPK. In vivo, LPA stimulates tumor metastasis in an orthotopic ovarian tumor model, which can be inhibited by a PI3K inhibitor, LY294002. In summary, LPA is likely a key component for promoting ovarian metastasis in vivo. LPA downregulates TIMP3, which may have targets other than metalloproteinases. Our in vivo metastasis mouse model is useful for studying the efficacy of therapeutic regimes of ovarian cancer.
Introduction
Ovarian cancer cells are highly migratory and invasive, although their spreading do not usually involve the blood stream . Migration and invasion are two of the common and most critical steps for tumor metastasis (Hartsough and Steeg, 2000) . Both of these processes can be studied in vitro. However, a complete metastatic process can only be assessed in vivo.
Lysophosphatidic acid (LPA), a biological active lipid signaling molecule, is elevated in ascites from patients with ovarian cancer (Xu et al., 1995a, b; Xiao et al., 2001) . More recently, we have shown that in addition to ovarian cancer cells (Shen et al., 1998; Eder et al., 2000) , peritoneal mesothelial cells from patients with ovarian cancer are able to produce LPA (Ren et al., 2006) . LPA regulates almost every aspect of ovarian cancer cell biology Mills et al., 2002; Mills and Moolenaar, 2003; Sengupta et al., 2004) . In particular, we and others have shown that LPA stimulates adhesion, migration and invasion of ovarian cancer cells (Sawada et al., 2002; Sengupta et al., 2003; Bian et al., 2004 Bian et al., , 2006 So et al., 2004 So et al., , 2005 Xu et al., 2004; Symowicz et al., 2005; Ren et al., 2006; Sugimoto et al., 2006) . Cell invasion induced by LPA involves protease (such as matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA)) activities (Pustilnik et al., 1999; Fishman et al., 2001; Bian et al., 2004; So et al., 2004 So et al., , 2005 Symowicz et al., 2005) . In addition, LPA stimulates secretion of proangiogenic factors, such as interleukin (IL)-8 Fang et al., 2004) and vascular endothelial growth factor (VEGF) (Hu et al., 2001) . have been shown to be involved in LPA-induced cell invasion (So et al., 2004 (So et al., , 2005 . Most, if not all, of these studies are conducted in established ovarian cancer cell lines.
In this work, we have determined the effect of LPA in cell invasion in primary ovarian cancer and non-cancer cells, investigated molecular mechanisms of LPAinduced invasion of ovarian cancer cells in vitro and utilized an orthotopic ovarian cancer mouse model to test the efficacy of a phosphatidylinositol-3 kinase (PI3K) inhibitor in blocking LPA-induced metastasis in vivo.
Results
LPA stimulates invasion of primary ovarian cancer cells, but not borderline or human ovarian surface epithelial cells LPA potently stimulated invasion of ovarian cancer cells. The number of cell invaded and the fold of stimulation by LPA were dependent on the number of cells used for invasion assays (Supplementary Information). As we would like to address the mechanisms of LPA-induced cell invasion versus the basal level cell invasion, we chose a condition (5 Â 10 5 HEY cells/ chamber) when the basal levels of invasion could be clearly observed. Under these conditions, an average twofold of LPA (100 nM)-induced cell invasion was observed ( Figure 1a ). In addition to HEY ovarian cancer cells, LPA (100 nM) also induced cell invasion in SKOV3, Ovca420 and OCC1 ovarian cancer cell lines ( Figure 1a and results not shown).
It is important to test whether LPA could also induce cell invasion in primary cells and whether this induction is malignant tumor cells specific. Thus, we established cells from primary ovarian cancers (one Stage IC tumor and four Stage IIIC serous adenocarcinoma tumors) and low malignant potential tumors (LMP or borderline tumors; from two patients). Cells derived from both primary and secondary sites (including the bowel and omentum) were established with tumors from patients with Stage IIIC serous adenocarcinoma ovarian cancer. All Stage IIIC tumor cells, regardless whether they were derived from the primary or a metastatic site, responded to LPA with an enhanced invasion (similar to that of the HEY ovarian cancer cell line). Cells from the Stage IC tumor had low invasive potential, but also responded to LPA (Figure 1a) .
In contrast, the borderline tumor cells (KBL1 and SEBo1, see Supplementary Information) and human ovarian surface epithelial (HOSE) cells did not invade in the presence or absence of LPA ( Figure 1a and data not shown). This is consistent with the nature of these cells and it is important to show that LPA-induced cell invasion is malignant cells specific. Interestingly and surprisingly, these cells responded to LPA in cell migration (Figure 1b) , suggesting the responsiveness to LPA is not unique to malignant cancer cells. Epidermal growth factor (EGF) also induced cell migration in both KBL1 and HOSE cells, but LPA was more potent than EGF in inducing cell migration (Figure 1b) . G i protein, PI3K, p38 MAP kinase and cPLA 2 are required for LPA-induced cell invasion We have previously shown that G i protein, PI3K, p38 mitogen-activated activated (MAPK) and cytosolic phospholipase A 2 (cPLA 2 ) are required for cell migration induced by LPA in HEY ovarian cancer cells (Sengupta et al., 2003) . We have observed that these signaling molecules were also required for LPA-induced cell invasion and PI3K and p38 are upstream of cPLA 2 (Supplementary Information).
LPA induces downregulation of TIMPs
The involvement of the MMP-tissue inhibitor of metalloproteinase (TIMP) axis in tumor metastasis has been extensively studied. LPA induce MMP2/9 in DOV13 ovarian cancer cells when high concentrations of LPA (40-200 mM) were used (Fishman et al., 2001) . To test if LPA stimulated MMP in HEY cells at the concentrations that stimulate invasion (50 nM-30 mM), we conducted zymographic assays in HEY cells and found that LPA (up to 30 mM) had no significant effect on the expression levels or the proteolytic processing of MMP2 and MMP9 (data not shown). Multiplex enzyme-linked immunosorbant assays (ELISA) were conducted to assess a broader spectrum of MMPs. To our surprise, LPA (100 nM, at which LPA effectively induce cell invasion) had an inhibitory effect on the secreted levels of MMP2, and 9 (Figure 2A, a) . In addition, LPA (100 nM) did not increase the enzymatic activity of MMP2/MMP9 (Figure 2A, b ). Among different MMPs tested (MMP-1, -2, -3, -8, -9, -10 and -13), LPA only increased the expression (Figure 2A , a) Interestingly, we observed that two negative regulators of MMPs, TIMP1 and TIMP2, were significantly downregulated by LPA ( Figure 2B , a and b). Western blot analysis revealed that secreted TIMP3 (that is not included in the multiplex ELISA assay) levels were also down regulated by LPA ( Figure 2B , c). Moreover, a cDNA array-based study showed that TIMP2 was downregulated by LPA at the RNA level to 46% and TIMP3 was downregulated by LPA to 64% (Supplementary Information).
To test if TIMPs were involved in invasion, we treated HEY cells with recombinant TIMP1, TIMP2 or TIMP3 (10 nM of each). TIMP2 and TIMP3 significantly reversed the LPA-induced cell invasion ( Figure 2C ), supporting the functional role of these molecules as negative regulators of cell invasion. However, as shown above, the expression levels and activities of most tested MMPs were not increased by LPA (100 nM), and TIMP3 did not affect LPA-induced MMP3 activity (data not shown), suggesting that TIMPs may have different targets in HEY ovarian cancer cells.
p38 MAPK signaling pathway and VEGFR2 are potential targets for TIMP3 As p38 MAPK was required for LPA-induced cell invasion (see above and Supplementary Information), we tested the possible effect of TIMPs on p38 phosphorylation, which had not been shown previously. Only a reversed effect of p38 MAPK on TIMP2 has been previously demonstrated (Munshi et al., 2004) . We observed that while TIMP1 and TIMP2 did not have a significant effect on LPA-induced p38 MAPK phosphorylation (data not shown), TIMP3 inhibited LPAinduced p38 MAPK phosphorylation ( Figure 3A, a) . To test whether the effect of TIMP3 on p38 phosphorylation is functionally required for its inhibitory effect on cell invasion induced by LPA, we transfected HEY cells with a constitutively active MKK6 (an upstream activator of p38 MAPK). This transfection reversed the inhibitory effect of TIMP3 on LPA-induced cell invasion ( Figure 3A, b) , suggesting that p38 is one of the potential downstream targets of TIMP3.
Recently, VEGF receptor 2 (VEGFR2) has been identified as a target for TIMP3, which inhibits VEGFR2 via competitive binding to this receptor (Qian et al., 2003) . More recently, LPA-induced cell invasion TIMPs are negative regulators of LPA-induced invasion S Sengupta et al and activation of MMP-2 and uPA in DOV13 ovarian cancer cells have been shown to be mediated by VEGFR2 (So et al., 2005) . Moreover, LPA induces VEGF secretion in ovarian cancer cells (Hu et al., 2001) , suggesting that VEGF (the ligand of VEGFR2) might be the mediator of the crosstalk between LPA and VEGFR. If VEGFR2 is a functional target for TIMP3 in HEY ovarian cancer cells, it should be involved in LPA-induced cell invasion and VEGF-induced cell invasion should be inhibited by TIMP3. We found that both a neutralizing antibody against VEGFR2 and a VEGFR2 tyrosine kinase inhibitor (VEGFRTki) significantly inhibited LPA (100 nM)-induced invasion ( Figure 3B, a) , suggesting that VEGFR is functionally involved in LPA-induced cell invasion. We then tested whether VEGF-induced cell invasion was affected by TIMP3. We found that VEGF (25 ng/ml) induced approximately B30% increase in invasion of HEY cells, which could be blocked by TIMP3 ( Figure 3B, b) , suggesting VEGFR is a potential target for TIMP3 in HEY cells.
To further elucidate the relationship between the two potential targets of TIMP3 (p38 MAPK and VEGFR2), we tested whether VEGFR2 was required for p38 phosphorylation. We found that VEGFR was not required for LPA-induced p38 activation, as VEGFRTki did not affect phosphorylation of p38 by LPA (data not shown), suggesting TIMP3 may have two separate and independent downstream targets.
Cell invasion requires a proteolytic activity to degrade the extracellular matrix. LPA induces uPA expression in ovarian cancer cells (Pustilnik et al., 1999; Li et al., 2005) . We also observed that LPA (100 nM) stimulated uPA expression and activity (data not shown). To determine the role of uPA in LPA-induced cell invasion in HEY cells, uPA expression was downregulated using a short interfering RNA (siRNA ) (Figure 3C , a). LPA-induced as well as the basal level cell invasion were partially inhibited by uPA siRNA (Figure 3C, b) . Interestingly, TIMP3 treatment and uPA siRNA showed an additive effect and completely blocked LPA-induced cell invasion ( Figure 3C, b) , suggesting that downregulation of TIMP3 (thereby removal of its inhibitory effect on p38 phosphorylation and VEGFR activation) and up-regulation of uPA may be two separate signaling pathways of LPA-induced invasion.
PI3K inhibitor effective reduced LPA-induced metastasis in vivo
We have recently shown, for the first time, that LPA stimulates tumor metastasis using an orthotopic ovarian cancer mouse model (Kim et al., 2006 ). This mouse model provides a very useful system to test TIMPs are negative regulators of LPA-induced invasion S Sengupta et al potential therapeutic reagents for the treatment of ovarian cancer.
The first choice for LPA blockage is at the level of the receptors. However, due to solubility and toxicity issues, we could not use the VPC compounds (antagonists of LPA receptors) provided by Drs Kevin Lynch and Timothy Macdonald to specifically block tumor metastasis (data not shown). As PI3K is an upstream effector in the LPA signaling pathway (Supplementary Information) and LY294002 has been shown to reduce ovarian tumor growth in a mouse model with intraperitoneally injected (i.p.) ovarian cancer cells (Hu et al., 2000) , we tested the efficacy of LY294002 (a PI3K antagonist) on blocking LPA-induced metastasis in vivo.
LPA exerted a significant effect on tumor metastasis in HEY and SKOV3 cell mouse model ( Figure 4A and B). LPA-treated mice had metastases to the mesentery, bowel, liver, body wall, and diaphragm, which resembles the metastatic pattern in human disease. PBS control mice also had metastases to these organs. However, the size and the number of loci in the LPA group were significantly higher than that of the PBS group. In particular, in the SKOV3 cell model, metastases were minimal in the absence and LPA, but greatly enhanced in the LPA-treated group ( Figure 4B, b) . At a concentration of 100 mg/kg body weight, LY294002 (administered thrice per week) significantly inhibited metastasis in both LPA and PBS groups and in tumors derived either from HEY or SKOV3 cell ( Figure 4A and B). These results suggest that PI3K represents a useful target for the treatment of ovarian cancer.
Discussion
LPA downregulates TIMPs, which may have two independent targets: p38 MAPK and VEGFR2 The role of the matrix-degrading enzymes, such as MMPs, uPA and the matrix-degrading inhibitory enzymes, TIMPs, have been reported in ovarian cancer (Sakata et al., 2000; Cai and Song, 2002; Casey et al., 2003; Manenti et al., 2003; Krol et al., 2003a; Hu et al., 2004; Rauvala et al., 2005) . LPA has been shown to stimulate uPA (Pustilnik et al., 1999; Krol et al., 2003b; Li et al., 2005; So et al., 2005) and MMP activity (Fishman et al., 2001) in DOV13 ovarian cancer cells. However, whether LPA also stimulates MMPs in other ovarian cancers cells were previously unknown. In addition, the MMP activity induced by LPA in DOV13 cells requires high concentrations (40-200 mM) (Fishman et al., 2001) , whereas the median level of LPA detected in human ovarian cancer ascites is 19-20 mM (Xiao et al., 2000 ) . We have shown here that very low concentrations of LPA (10-100 nM) are potent in invasion stimulation (Figure 1a ). At these concentrations, expression and/or activities of a number of MMPs, including MMP-1, -2, -8, -9, -10 and -13 ( Figure  4A , c) were not increased by LPA. Although LPA has a stimulatory effect on MMP3, the basal expression level of MMP3 was low and the stimulation by LPA was not very strong. The role of additional MMPs (including MT1-MMP) in LPA-induced cell invasion in HEY ovarian cancer cells are not directly assessed and remain to be further investigated. Interestingly, we have found that TIMPs are downregulated by LPA (Figure 3) . Whereas the MMPs are the most extensively studied targets for TIMPs, other targets may also exist. Recent work shows that VEGFR (Qian et al., 2003) and a 3 b 1 -integrin (Seo et al., 2003) are the novel targets of TIMP3 and TIMP2, respectively. Our results show that VEGFR2 and p38 MAPK signaling pathways may be two independent downstream targets of TIMP3, which warrant further investigations on whether TIMP3 directly targets and how TIMP3 targets these molecules. Our observations are consistent with the negative role of TIMP in cell invasion and the potential therapeutic usage of TIMPs as ovarian cancer therapeutics (Krol et al., 2003b) .
Multiple independent signaling pathways appear to be involved in LPA-induced cell invasion. For example, LPA-stimulated VEGF secretion may be involved in LPA-induced cell invasion (So et al., 2005) . However, the activity of VEGF is less potent than LPA ( Figure 3B ), suggesting LPA-induced multiple signaling molecules/pathways. This notion is supported by the partial inhibition observed when TIMPs admission or uPA downregulation were conducted separately and the additive and complete inhibition achieved when both of them were present. This concept may be important for developing therapeutic strategy to block metastasis.
Both benign and malignant cancer cells respond to LPA in cell migration, but not cell invasion In previous studies, differential response to LPA in benign and malignant cells have been proposed or shown Fang et al., 2004) . Differential receptor expression has been proposed as one of the major reasons for these differences. Our studies here, however, suggest that at least in some benign cells, LPA receptors are expressed and functional. They can respond to LPA in cell migration. However, these cells do not invade and do not respond to LPA in cell invasion, which are consistent to their pathophysiological nature. One of the major changes in malignant and invasive cancer cells is their enhanced protease activities, which has been observed in many cancers. Our results further suggest that reduced inhibitory effect may also play an important role in promoting the invasive ability of cancer cells. These issues warrant further investigation.
PI3K inhibitor effectively blocks metastasis in vivo
We have shown that PI3K is upstream of p38 MAPK (Baudhuin et al., 2002) and cPLA 2 (Supplementary Figure 2) . In addition, PI3K mediates many important LPA effects, including cell proliferation, antiapoptosis, migration and invasion. Recently, the clinical potential of blocking PI3K as a novel therapeutic treatment for human ovarian cancer has attracted a great deal of interest (Hennessy et al., 2005) . Thus, we chose to inhibit the PI3K to provide a proof-of-principle example using the orthotopic ovarian mouse model. Although LY294002 has been shown to be effective in ovarian cancer tumorigenesis in an i.p. injection mouse model (Hu et al., 2002) , our mouse model has the advantage to assess it effect on tumor growth and metastasis separately. Our results showed that LY294002 had a minimal effect on primary tumor sizes on the ovaries, but strongly inhibited tumor metastasis in our mouse model. This concept is interesting and important in developing novel therapeutics targeting PI3K (Hennessy et al., 2005) . Consistent with the previous report using i.p. injection (Hu et al., 2002) , we show that LY294002, at the concentration used, is not cytotoxic and effective in reducing ovarian tumor development. Our results suggest that the orthotopic mouse model can be very useful in testing other therapeutic reagents for the treatment of metastatic ovarian cancer.
In summary, our work shows that LPA induces cell invasion in primary cancer cells, which is important as established cell lines undergone multiple adaptations to long-term cell culture, compromising their accuracy in representing the original cancers. We have identified new signaling molecules involved in LPA-induced cell invasion, which will help us to develop novel target(s) for therapeutics for the treatment of ovarian cancer. Importantly, we have provided the first-line evidence that TIMPs can be regulated by LPA and its downregulation is functionally involved in LPA-induced cell invasion. Future investigations are warranted to test and validate whether TIMPs are useful therapeutic reagents for ovarian cancer.
Materials and methods

Reagents
Delta-p85 (dominant-negative PI3K), mitogen-activated protein kinase (MKK)6 and p38 AGF (a kinase-inactive form of p38 MAPK) were kind gifts from Dr Alan Wolfman (The Cleveland Clinic Foundation, Cleveland, OH, USA). 18:1 oleyl LPA and (2S)-1-oleoyl-2-O-methyl-glycero-3-phosphothionate (OMPT) were from Avanti Polar Lipids (Birmingham, Al). si-RNA against uPA (5 0 -UGAUAUCACUGGCUUUGGA UU-3 0 ) was a kind gift from Dr S Huang, Department of Immunology, The Scripps Research Inst., CA 92037, USA. Anti-phospho p38 MAPK, total p38 MAPK was from Cell Signaling (Beverly, MA, USA), and anti-uPA was a gift from Dr Graham Casey (Cleveland Clinic, OH, USA).
Cells and transfection, invasion assays, expression and activity assays of MMPs and TIMPs, as well as the orthotopic mouse ovarian cancer model are described in the Supplementary Information. ovarian tumor cells. We thank Drs Kevin Lynch and Timothy MacDonald (University of Virginia, Charlottesville, VA, USA) for providing us with VPC32301 and VPC32073 (antagonists of LPA receptors). We also thank Dr S Huang (The Scripps Research Institute) for the siRNA targeting to uPA. This work was supported in part by RO1 CA095042 and a grant from the Charlotte Geyer Foundation to YX.
